Hepatitis Monthly

Published by: Kowsar

Immunization of Mice by BCG Formulated HCV Core Protein Elicited Higher Th1-Oriented Responses Compared to Pluronic-F127 Copolymer

Maryam Yazdanian 1 , Arash Memarnejadian 1 , * , Mehdi Mahdavi 2 , Seyed Mehdi Sadat 1 , Fatemeh Motevali 1 , Rouhollah Vahabpour 1 , Hossein Khanahmad 3 , Seyed Davar Siadat 4 , Mohammad Reza Aghasadeghi 1 and Farzin Roohvand 2 , *
Authors Information
1 Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, IR Iran
2 Virology Department, Pasteur Institute of Iran, Tehran, IR Iran
3 BCG Research Center, Karaj Research and Production Complex, Pasteur Institute of Iran, Karaj, IR Iran
4 Microbiology Department, Pasteur Institute of Iran, Tehran, IR Iran
Corresponding Authors:
Article information
  • Hepatitis Monthly: October 01, 2013, 13 (10); e14178
  • Published Online: October 23, 2013
  • Article Type: Research Article
  • Received: August 13, 2013
  • Revised: September 14, 2013
  • Accepted: September 25, 2013
  • DOI: 10.5812/hepatmon.14178

To Cite: Yazdanian M, Memarnejadian A, Mahdavi M, Sadat S M, Motevali F, et al. Immunization of Mice by BCG Formulated HCV Core Protein Elicited Higher Th1-Oriented Responses Compared to Pluronic-F127 Copolymer, Hepat Mon. 2013 ; 13(10):e14178. doi: 10.5812/hepatmon.14178.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Chevaliez S, Pawlotsky JM. Virology of hepatitis C virus infection. Best Pract Res Clin Gastroenterol. 2012; 26(4): 381-9[DOI][PubMed]
  • 2. Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, et al. Hepatitis C virus vaccines--progress and perspectives. Microb Pathog. 2013; 58: 66-72[DOI][PubMed]
  • 3. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design. Expert Opin Ther Pat. 2011; 21(12): 1811-30[DOI][PubMed]
  • 4. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert Opin Ther Pat. 2012; 22(4): 391-415[DOI][PubMed]
  • 5. Lauer GM. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. J Infect Dis. 2013; 207 Suppl 1[DOI][PubMed]
  • 6. Swadling L, Klenerman P, Barnes E. Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther. 2013; 13(8): 1109-24[DOI][PubMed]
  • 7. Prabdial-Sing N, Puren AJ, Bowyer SM. Sequence-based in silico analysis of well studied hepatitis C virus epitopes and their variants in other genotypes (particularly genotype 5a) against South African human leukocyte antigen backgrounds. BMC Immunol. 2012; 13: 67[DOI][PubMed]
  • 8. Arashkia A, Roohvand F, Memarnejadian A, Aghasadeghi MR, Rafati S. Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice. Virus genes. 2010; 40(1): 44-52[DOI][PubMed]
  • 9. Memarnejadian A, Roohvand F. Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine. Cell Immunol. 2010; 261(2): 93-8[DOI][PubMed]
  • 10. Memarnejadian A, Roohvand F, Arashkia A, Rafati S, Shokrgozar MA. Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. Protein Pept Lett. 2009; 16(7): 842-50[PubMed]
  • 11. Baghbani-arani F, Roohvand F, Aghasadeghi MR, Eidi A, Amini S, Motevalli F, et al. Expression and characterization of Escherichia coli derived hepatitis C virus ARFP/F protein. Mol Biol (Mosk). 2012; 46(2): 251-9[PubMed]
  • 12. Budkowska A, Kakkanas A, Nerrienet E, Kalinina O, Maillard P, Horm SV, et al. Synonymous mutations in the core gene are linked to unusual serological profile in hepatitis C virus infection. PLoS One. 2011; 6(1)[DOI][PubMed]
  • 13. Jahan S, Ashfaq UA, Khaliq S, Samreen B, Afzal N. Dual behavior of HCV Core gene in regulation of apoptosis is important in progression of HCC. Infect Genet Evol. 2012; 12(2): 236-9[DOI][PubMed]
  • 14. Zhu W, Chang Y, Wu C, Han Q, Pei R, Lu M, et al. The wild-type hepatitis C virus core inhibits initiation of antigen-specific T- and B-cell immune responses in BALB/c mice. Clin Vaccine Immunol. 2010; 17(7): 1139-47[DOI][PubMed]
  • 15. Roohvand F, Aghasadeghi MR, Sadat SM, Budkowska A, Khabiri AR. HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. Biochem Biophys Res Commun. 2007; 354(3): 641-9[DOI][PubMed]
  • 16. Cerutti A, Maillard P, Minisini R, Vidalain PO, Roohvand F, Pecheur EI, et al. Identification of a functional, CRM-1-dependent nuclear export signal in hepatitis C virus core protein. PLoS One. 2011; 6(10)[DOI][PubMed]
  • 17. Acosta-Rivero N, Duenas-Carrera S, Alvarez-Lajonchere L, Morales-Grillo J. HCV core protein-expressing DNA vaccine induces a strong class I-binding peptide DTH response in mice. Biochem Biophys Res Commun. 2004; 314(3): 781-6[PubMed]
  • 18. Hosseini SY, Sabahi F, Moazzeni SM, Modarressi MH, Saberi Firoozi M, Ravanshad M. Construction and preparation of three recombinant adenoviruses expressing truncated NS3 and core genes of hepatitis C virus for vaccine purposes. Hepat Mon. 2012; 12(8)[DOI][PubMed]
  • 19. Isaguliants MG, Petrakova NV, Kashuba EV, Suzdaltzeva YG, Belikov SV, Mokhonov VV, et al. Immunization with hepatitis C virus core gene triggers potent T-cell response, but affects CD4+ T-cells. Vaccine. 2004; 22(13-14): 1656-65[DOI][PubMed]
  • 20. Liao G, Wang Y, Chang J, Bian T, Tan W, Sun M, et al. Hepatitis B virus precore protein augments genetic immunizations of the truncated hepatitis C virus core in BALB/c mice. Hepatology. 2008; 47(1): 25-34[DOI][PubMed]
  • 21. Brunner R, Jensen-Jarolim E, Pali-Scholl I. The ABC of clinical and experimental adjuvants--a brief overview. Immunol Lett. 2010; 128(1): 29-35[DOI][PubMed]
  • 22. Cassidy A, Mossman S, Olivieri A, De Ridder M, Leroux-Roels G. Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity. Expert Rev Vaccines. 2011; 10(12): 1709-15[DOI][PubMed]
  • 23. Schijns VE, Brewer JM. New views on immunopotentiators in modern vaccines. Expert Rev Vaccines. 2008; 7(7): 877-9[DOI][PubMed]
  • 24. Naarding MA, Falkowska E, Xiao H, Dragic T. Hepatitis C virus soluble E2 in combination with QuilA and CpG ODN induces neutralizing antibodies in mice. Vaccine. 2011; 29(16): 2910-7[DOI][PubMed]
  • 25. Andreasen SO, Christensen JE, Marker O, Thomsen AR. Role of CD40 ligand and CD28 in induction and maintenance of antiviral CD8+ effector T cell responses. J Immunol. 2000; 164(7): 3689-97[PubMed]
  • 26. Salem ML, El-Demellawy M, El-Azm AR. The potential use of Toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus. Cell Immunol. 2010; 262(2): 96-104[DOI][PubMed]
  • 27. Villarreal-Ramos B. Towards improved understanding of protective mechanisms induced by the BCG vaccine. Expert Rev Vaccines. 2009; 8(11): 1531-4[DOI][PubMed]
  • 28. Heldwein KA, Liang MD, Andresen TK, Thomas KE, Marty AM, Cuesta N, et al. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J Leukoc Biol. 2003; 74(2): 277-86[PubMed]
  • 29. von Meyenn F, Schaefer M, Weighardt H, Bauer S, Kirschning CJ, Wagner H, et al. Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guerin by Flt3-ligand generated dendritic cells. Immunobiology. 2006; 211(6-8): 557-65[DOI][PubMed]
  • 30. Fujii R, Iwahashi M, Kikkawa K, Inagaki T, Kohjimoto Y, Ojima T, et al. Bacillus Calmette-Guerin cell-wall skeleton enhances the killing activity of cytotoxic lymphocyte-activated human dendritic cells transduced with the prostate-specific antigen gene. BJU Int. 2009; 104(11): 1766-73[PubMed]
  • 31. Klein MR, McAdam KP. CD8+ T lymphocytes against mycobacterium tuberculosis. Arch Immunol Ther Exp (Warsz). 1999; 47(5): 313-20[PubMed]
  • 32. Takamura S, Matsuo K, Takebe Y, Yasutomi Y. Ag85B of mycobacteria elicits effective CTL responses through activation of robust Th1 immunity as a novel adjuvant in DNA vaccine. J Immunol. 2005; 175(4): 2541-7[PubMed]
  • 33. Dietrich J, Billeskov R, Doherty TM, Andersen P. Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. J Immunol. 2007; 178(6): 3721-30[PubMed]
  • 34. Ravindran R, Bhowmick S, Das A, Ali N. Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis. BMC Microbiol. 2010; 10: 181[DOI][PubMed]
  • 35. Armijos RX, Weigel MM, Calvopina M, Hidalgo A, Cevallos W, Correa J. Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine. 2004; 22(9-10): 1320-6[DOI][PubMed]
  • 36. Bhowmick S, Ali N. Recent developments in leishmaniasis vaccine delivery systems. Expert Opin Drug Deliv. 2008; 5(7): 789-803[DOI][PubMed]
  • 37. Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasseri K, et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine. 2008; 26(52): 6759-67[DOI][PubMed]
  • 38. Pearce EJ, James SL, Hieny S, Lanar DE, Sher A. Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen. Proc Natl Acad Sci U S A. 1988; 85(15): 5678-82[PubMed]
  • 39. Araujo Z, El Bouhdidi A, Heremans H, Van Marck E, Castes M, Carlier Y. Vaccination of mice with a combination of BCG and killed Leishmania promastigotes reduces acute Trypanosoma cruzi infection by promoting an IFN-gamma response. Vaccine. 1999; 17(7-8): 957-64[PubMed]
  • 40. Uno-Furuta S, Matsuo K, Tamaki S, Takamura S, Kamei A, Kuromatsu I, et al. Immunization with recombinant Calmette-Guerin bacillus (BCG)-hepatitis C virus (HCV) elicits HCV-specific cytotoxic T lymphocytes in mice. Vaccine. 2003; 21(23): 3149-56[PubMed]
  • 41. Wei SH, Yin W, An QX, Lei YF, Hu XB, Yang J, et al. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen. Arch Virol. 2008; 153(6): 1021-9[DOI][PubMed]
  • 42. Maillard P, Lavergne JP, Siberil S, Faure G, Roohvand F, Petres S, et al. Fcgamma receptor-like activity of hepatitis C virus core protein. J Biol Chem. 2004; 279(4): 2430-7[DOI][PubMed]
  • 43. Roohvand F, Maillard P, Lavergne JP, Boulant S, Walic M, Andreo U, et al. Initiation of hepatitis C virus infection requires the dynamic microtubule network: role of the viral nucleocapsid protein. J Biol Chem. 2009; 284(20): 13778-91[DOI][PubMed]
  • 44. Hu GJ, Wang RY, Han DS, Alter HJ, Shih JW. Characterization of the humoral and cellular immune responses against hepatitis C virus core induced by DNA-based immunization. Vaccine. 1999; 17(23-24): 3160-70[PubMed]
  • 45. Ingulli E. Tracing tolerance and immunity in vivo by CFSE-labeling of administered cells. Methods Mol Biol. 2007; 380: 365-76[DOI][PubMed]
  • 46. Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, Mosmann TR, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature. 1988; 334(6179): 255-8[DOI][PubMed]
  • 47. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005; 436(7053): 946-52[DOI][PubMed]
  • 48. Mutiso JM, Macharia JC, Kariuki TM, Gicheru MM. Montanide ISA 720 is more effective than BCG as an adjuvant for Leishmania killed vaccine in BALB/c mice. Int J Integ Biol. 2009; 7(2)
  • 49. Santos WR, de Lima VM, de Souza EP, Bernardo RR, Palatnik M, Palatnik de Sousa CB. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine. 2002; 21(1-2): 30-43[PubMed]
  • 50. Tonui WK, Mpoke SS, Orago AS, Turco SJ, Mbati PA, Mkoji GM. Leishmania donovani-derived lipophosphoglycan plus BCG induces a Th1 type immune response but does not protect Syrian golden hamsters (Mesocricetus auratus) and BALB/c mice against Leishmania donovani. Onderstepoort J Vet Res. 2003; 70(4): 255-63[PubMed]
  • 51. Bastos RG, Borsuk S, Seixas FK, Dellagostin OA. Recombinant Mycobacterium bovis BCG. Vaccine. 2009; 27(47): 6495-503[DOI][PubMed]
  • 52. Wang H, Su X, Zhang P, Liang J, Wei H, Wan M, et al. Recombinant heat shock protein 65 carrying PADRE and HBV epitopes activates dendritic cells and elicits HBV-specific CTL responses. Vaccine. 2011; 29(12): 2328-35[DOI][PubMed]
  • 53. Barber DL, Wherry EJ, Ahmed R. Cutting edge: rapid in vivo killing by memory CD8 T cells. J Immunol. 2003; 171(1): 27-31[PubMed]
  • 54. Lanier JG, Newman MJ, Lee EM, Sette A, Ahmed R. Peptide vaccination using nonionic block copolymers induces protective anti-viral CTL responses. Vaccine. 1999; 18(5-6): 549-57[PubMed]
  • 55. Todd CW, Balusubramanian M, Newman MJ. Development of adjuvant-active nonionic block copolymers. Adv Drug Deliv Rev. 1998; 32(3): 199-223[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments